Similar articles

• Solifenacin in the management of the overactive bladder syndrome.

  Robinson D, Cardozo L. Robinson D, et al. Int J Clin Pract. 2005 Oct;59(10):1229-36. doi: 10.1111/j.1368-5031.2005.00628.x. Int J Clin Pract. 2005. PMID: 16178992 Review.
• Co-administration of an α(1) -blocker improves the efficacy and safety of antimuscarinic agents in rats with detrusor overactivity.

  Nagase K, Ito H, Aoki Y, Tanase K, Akino H, Yokoyama O. Nagase K, et al. Int J Urol. 2011 Dec;18(12):836-43. doi: 10.1111/j.1442-2042.2011.02868.x. Epub 2011 Oct 13. Int J Urol. 2011. PMID: 21995543
• Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN).

  Van Kerrebroeck P, Haab F, Angulo JC, Vik V, Katona F, Garcia-Hernandez A, Klaver M, Traudtner K, Oelke M. Van Kerrebroeck P, et al. Eur Urol. 2013 Sep;64(3):398-407. doi: 10.1016/j.eururo.2013.03.031. Epub 2013 Mar 19. Eur Urol. 2013. PMID: 23537687 Clinical Trial.
• [Pharmacological and clinical profile of solifenacin succinate (Vesicare) developed as a new therapeutic agent for overactive bladder].

  Ohtake A, Sato S, Ikeda K, Sasamata M, Miyata K. Ohtake A, et al. Nihon Yakurigaku Zasshi. 2006 Dec;128(6):425-32. doi: 10.1254/fpj.128.425. Nihon Yakurigaku Zasshi. 2006. PMID: 17167217 Review. Japanese. No abstract available.
• Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency.

  Kaplan SA, McCammon K, Fincher R, Fakhoury A, He W. Kaplan SA, et al. J Urol. 2009 Dec;182(6):2825-30. doi: 10.1016/j.juro.2009.08.023. Epub 2009 Oct 17. J Urol. 2009. PMID: 19837435 Clinical Trial.